Literature DB >> 10943594

Stability of YKL-40 concentration in blood samples.

E V Høgdall1, J S Johansen, S K Kjaer, P A Price, J Blaakjaer, C K Høgdall.   

Abstract

The stability of YKL-40, a mammalian member of the family of 18 glycosylhydrolases, in blood samples handled under different temperatures and different time intervals before centrifugation was studied in paired serum and plasma samples from 25 healthy premenopausal Danish women. Significant elevations of YKL-40 were found in 8 paired serum samples left on the clot for more than 3 h at room temperature compared to paired serum samples left on the clot for 3 h or less. Significant elevations of YKL-40 were found in 8 paired plasma (EDTA) samples left on the blood cells for more than 8 h at room temperature compared to paired plasma (EDTA) samples left on the blood cells for 8 h or less. No elevations were found in YKL-40 levels in serum samples left on the clot at 4 degrees C for 24 h or in plasma (EDTA) samples left on the blood cells for 72 h before centrifugation. Significantly lower concentrations of YKL-40 were measured in plasma (EDTA) compared with paired serum samples with a serum/plasma ratio of 1.4 in samples left on the clot or on blood cells at 4 degrees C for up to 24 h. Repetitive freezing and thawing had no significant effect on the measured YKL-40 concentrations. In conclusion, we have shown that YKL-40 is very dependent on the handling procedures. All the blood samples must be processed into plasma (EDTA) within 8 h at room temperature or into serum in less than 3 h at room temperature. If this is not possible, the blood samples must be stored at 4 degrees C until processed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943594     DOI: 10.1080/00365510050184886

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  9 in total

1.  Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review.

Authors:  Daniela Pierscianek; Yahya Ahmadipour; Marvin Darkwah Oppong; Laurèl Rauschenbach; Sied Kebir; Martin Glas; Ulrich Sure; Ramazan Jabbarli
Journal:  Mol Neurobiol       Date:  2019-02-04       Impact factor: 5.590

2.  Serum YKL-40 following resection for cerebral glioblastoma.

Authors:  Daniela Bernardi; Andrea Padoan; Andrea Ballin; Mariateresa Sartori; Renzo Manara; Renato Scienza; Mario Plebani; Alessandro Della Puppa
Journal:  J Neurooncol       Date:  2011-11-19       Impact factor: 4.130

3.  Serum and plasma neutrophil gelatinase associated lipocalin (NGAL) levels are not equivalent in patients admitted to intensive care.

Authors:  Theis Skovsgaard Itenov; Kristian Bangert; Per Hjort Christensen; Jens-Ulrik Jensen; Morten Heiberg Bestle
Journal:  J Clin Lab Anal       Date:  2014-01-06       Impact factor: 2.352

4.  Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.

Authors:  Robert J Biggar; Julia S Johansen; Karin Ekström Smedby; Klaus Rostgaard; Ellen T Chang; Hans-Olov Adami; Bengt Glimelius; Daniel Molin; Stephen Hamilton-Dutoit; Mads Melbye; Henrik Hjalgrim
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

5.  YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.

Authors:  B Kornblit; T Wang; S J Lee; S R Spellman; X Zhu; K Fleischhauer; C Müller; M R Verneris; K Müller; J S Johansen; L Vindelov; P Garred
Journal:  Bone Marrow Transplant       Date:  2016-07-18       Impact factor: 5.483

6.  YKL-40 Level and Hypertension Incidence: A Population-Based Nested Case-Control Study in China.

Authors:  Tian Xu; Chongke Zhong; Aili Wang; Zhirong Guo; Xiaoqing Bu; Yipeng Zhou; Yunfan Tian; Xinfeng HuangFu; Zhengbao Zhu; Yonghong Zhang
Journal:  J Am Heart Assoc       Date:  2016-11-04       Impact factor: 5.501

Review 7.  Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry.

Authors:  Jose L Luque-Garcia; Thomas A Neubert
Journal:  J Chromatogr A       Date:  2006-12-12       Impact factor: 4.759

8.  YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Authors:  Estrid V S Høgdall; Merete Ringsholt; Claus K Høgdall; Ib Jarle Christensen; Julia S Johansen; Susanne K Kjaer; Jan Blaakaer; Lene Ostenfeld-Møller; Paul A Price; Lise H Christensen
Journal:  BMC Cancer       Date:  2009-01-09       Impact factor: 4.430

9.  YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?

Authors:  Nicolai A Schultz; Julia S Johansen
Journal:  Cancers (Basel)       Date:  2010-07-12       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.